Skip to main content

Coherus Oncology, Inc.

corporate_fare Company Profile

Coherus Oncology, Inc.

CHRS·NASDAQ·Life Sciences·CIK 0001512762

Coherus Oncology, Inc. is a commercial-stage oncology company focused on innovative cancer treatments. The company's primary product is LOQTORZI® (toripalimab-tpzi), an approved next-generation programmed death receptor-1 ("PD-1") inhibitor. LOQTORZI was approved by the U.S. Food and Drug Administration ("FDA") on October 27, 2023, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma ("NPC") in combination with cisplatin and gemcitabine. It is also approved as a monotherapy for adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI, an anti-PD-1 antibody, was developed in collaboration with Junshi Biosciences Co., Ltd. and launched in the U.S. on January 2, 2024. It is currently the only FDA-approved immune checkpoint inhibitor for these NPC indications commercially available in the United States. The company's strategy involves growing LOQTORZI sales in NPC and developing new indications for LOQTORZI in combination with its pipeline candidates and partners. Coherus Oncology, Inc. changed its corporate name from "Coherus BioSciences, Inc." on May 29, 2025, to reflect its exclusive focus on proprietary immuno-oncology medicines following the divestitures of its biosimilar businesses. The pipeline includes two mid-stage clinical candidates targeting liver, head and neck, colorectal, and other cancers, which are planned for development in combination with LOQTORZI and other immune activating or cancer agents. One such candidate is casdozokitug (CHS-388, formerly SRF388), an investigational antagonist antibody targeting IL-27, which received orphan drug designation from the FDA for hepatocellular carcinoma ("HCC") in October 2020.

Coherus Oncology, Inc. (NASDAQ:CHRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CHRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CHRS spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Coherus 10-Q: Going-Concern Doubt With $83.6M Cash After $14.3M Q3 Revenue
  • Coherus Q3 Revenue Misses; Cuts ~30% of Staff, Narrows Pipeline to Esophageal Cancer
  • Coherus Q3 Revenue Misses at $14.3M, Net Loss Widens to $39.3M
  • Coherus Tagmokitug Hits 75% ORR in Front-Line Esophageal Cancer
  • Coherus Hires Oppenheimer to Sell Legacy Biosimilar Assets

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$42.17M
Net Income
$168.02M
Diluted EPS
$1.43
Op. Cash Flow
-$138.51M
Gross Profit
$28.36M
Operating Income
-$181.13M
Cash & Equivalents
$88.88M
Debt / Equity
0.00×
Net Margin
398.4%
Shares Outstanding
121.15M sh
Source: 10-K · filed 2026-03-09 · accession 0001104659-26-025308

Short Interest & Short Volume

8.20 days to cover

FINRA reported short interest of 12,712,857 shares in CHRS as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 19, 2026, 61.0% of CHRS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,712,857 shares as of October 30, 2026
Change vs prior period▲ 2.1%
Days to cover8.20 at avg daily volume of 1,551,288
Daily short volume (FINRA facilities)61.0% of 2,471,398 shares on November 19, 2026
5-day average short volume57.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CHRS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.

1 recent capital raiseATM program

New $50M ATM Program Established · Replaces Terminated $64.9M ATM

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.3729 -3.67% today
52-week range · as of 2026-11-09 $0.3729 – $2.62
Market cap
$56.86M
Volume
2.2M (1.0× avg)
3-mo avg 2.3M
Live data · 2026-11-20 20:47 UTC · Market open

show_chartPrice Chart

Loading chart...

feed CHRS - Latest Insights

CHRS
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8008
Real-time Price: $0.3729 info
Change: -$0.4279 (-53%) info
Market Cap: $56.862M info
CHRS
Nov 09, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7976
Real-time Price: $0.3729 info
Change: -$0.4247 (-53%) info
Market Cap: $56.862M info
CHRS
Nov 09, 2026, 4:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.3729 info
Change: -$0.3971 (-52%) info
Market Cap: $56.862M info
CHRS
Oct 29, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.3729 info
Change: -$0.6771 (-64%) info
Market Cap: $56.862M info
CHRS
Sep 23, 2026, 1:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.3729 info
Change: -$0.8721 (-70%) info
Market Cap: $56.862M info
CHRS
Aug 17, 2026, 5:36 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.3729 info
Change: -$0.8571 (-70%) info
Market Cap: $56.862M info
CHRS
Aug 17, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.3729 info
Change: -$0.7871 (-68%) info
Market Cap: $56.862M info
CHRS
Aug 17, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.3729 info
Change: -$0.7871 (-68%) info
Market Cap: $56.862M info
CHRS
Aug 05, 2026, 5:14 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.38
Real-time Price: $0.3729 info
Change: -$1.01 (-73%) info
Market Cap: $56.862M info
CHRS
Aug 05, 2026, 4:50 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $0.3729 info
Change: -$1.04 (-74%) info
Market Cap: $56.862M info
CHRS
Aug 05, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.3729 info
Change: -$1.04 (-74%) info
Market Cap: $56.862M info
CHRS
Jun 23, 2026, 2:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.3729 info
Change: -$1.11 (-75%) info
Market Cap: $56.862M info
CHRS
Jun 01, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.64
Real-time Price: $0.3729 info
Change: -$1.27 (-77%) info
Market Cap: $56.862M info
CHRS
May 28, 2026, 6:05 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.3729 info
Change: -$1.24 (-77%) info
Market Cap: $56.862M info
CHRS
May 11, 2026, 4:43 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.81
Real-time Price: $0.3729 info
Change: -$1.44 (-79%) info
Market Cap: $56.862M info
CHRS
May 11, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $0.3729 info
Change: -$1.49 (-80%) info
Market Cap: $56.862M info
CHRS
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $0.3729 info
Change: -$1.52 (-80%) info
Market Cap: $56.862M info
CHRS
May 05, 2026, 4:44 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $0.3729 info
Change: -$1.42 (-79%) info
Market Cap: $56.862M info
CHRS
Apr 20, 2026, 8:26 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.92
Real-time Price: $0.3729 info
Change: -$1.55 (-81%) info
Market Cap: $56.862M info
CHRS
Apr 09, 2026, 5:26 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.65
Real-time Price: $0.3729 info
Change: -$1.28 (-77%) info
Market Cap: $56.862M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets